A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

Exclusion Criteria

• •* Active ocular or peri-ocular infection in either eye
• •* Active, suspected intraocular inflammation in either eye at enrollment/baseline visit
• •* Hypersensitive to ACP or to any ingredient in the formulation
• •Patients currently participating in an investigational program with interventions outside of routine clinical practice.
• •Patients who have received ACP in the study eye. Note: Patients who have received or are receiving ACP in the fellow eye are eligible to be included in the study.
• •Patients who have received any intravitreal complement inhibitor other than ACP in either eye. Note: Patients who have received an intravitreal complement inhibitor other than ACP in either eye and have completed the 90-day washout period are eligible to be included in the study.